Sign in
CompletedPhase 2

A Prospective, One-arm and Open Clinical Study of CM313 in the Treatment of Immune Thrombocytopenia

Key facts

Who runs it
Institute of Hematology & Blood Diseases Hospital, China
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 2
People taking part
22 people enrolled
Started
22 Jan 2023
Ended
30 Dec 2023
Type of study
Interventional
Treatments tested
  • CM313 Injection
Record updated
24 February 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (24)Hide the full registry criteria

Who can take part

  • Age 18 and above, male or female
  • Conform to the diagnostic criteria of immune Thrombocytopenia (ITP)
  • Diagnosis of ITP ≥3 months, and with a platelet count of <30 X 109/L measured within 2 days prior to inclusion
  • Failure to achieve response or relapse after corticosteroid therapy, and at least one second-line therapy including rituximab or TPORAs
  • The previous emergency treatment of ITP (e.g. methylprednisolone, platelet transfusion, IVIG transfusion) must be completed at least 2 weeks before the first administration
  • Signed and dated written informed consent
  • With normal hepatic and renal functions
  • ECOG physical state score ≤ 2 points
  • Cardiac function of the New York Society of Cardiac Function ≤ 2
  • Patients receiving maintenance treatment (including corticosteroids (less than or equal to 0.5mg/kg prednisone), TPO receptor agonists, etc.) must have a stable dose at least 4 weeks before the first administration, and azathioprine, danazol, cyclosporin A, tacrolimus, sirolimus, etc. must be stopped at least 4 weeks before the first administration; The end of rituximab treatment was>3 months;More than 6 months after splenectomy; April 10, 2023 After approval by the Ethics Committee on , subjects no longer require platelet glycoprotein autoantibodies positivity upon enrollment

Who cannot take part

  • Received any treatment of anti-CD38 antibody drug
  • Those who have received allogeneic stem cell transplantation or organ transplantation in the past
  • Patients taking antiplatelet drugs at the same time
  • Uncontrollable primary diseases of important organs, such as malignant tumors, liver failure, heart failure, renal failure and other diseases
  • HIV positive
  • Accompanied by uncontrollable active infection, including hepatitis B, hepatitis C, cytomegalovirus, EB virus and syphilis positive
  • Accompanied by extensive and severe bleeding, such as hemoptysis, upper gastrointestinal hemorrhage, intracranial hemorrhage, etc
  • At present, there are heart diseases, arrhythmias that need treatment or hypertension that researchers judge is poorly controlled
  • Patients with thrombotic diseases such as pulmonary embolism, thrombosis and atherosclerosis
  • Patients with mental disorders who cannot normally obtain informed consent and conduct trials and follow-up
  • Other serious diseases that may limit the subject's participation in this test (such as diabetes; Severe cardiac insufficiency; Myocardial obstruction or unstable arrhythmia or unstable angina pectoris in recent 6 months; Gastric ulcer, etc.)
  • Patients with septicemia or other irregular severe bleeding
  • Patients whose toxic symptoms caused by pre-trial treatment have not disappeared
  • Pregnant women, suspected pregnancies (positive pregnancy test for human chorionic gonadotropin in urine at screening) and lactating patients

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To evaluate the safety and efficacy of CM313 in the treatment of immune thrombocytopenia in patients who have not responded adequately or relapsed after first-line treatment and at least one second-line therapy including rituximab and/or TPO-RA.

The group in the trial

  • Intervention (CM313)Treatment being tested

    20 enrolled subjects: once a week x 8 doses

    Treatment: CM313 Injection

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Prospective, One-arm and Open Clinical Study to Assess Safety and Efficacy of Anti-Human CD38 Monoclonal Antibody CM313 in the Treatment of Primary Immune Thrombocytopenia
Publications
Record updated
24 February 2025